Some studies, mostly including patients younger than 70, have shown that age does not affect patient's preferences [ 19] and that most patients consider 6 months of adjuvant CMF chemotherapy worthwhile for relatively modest survival gains [ 20].
Docetaxel is the first-line chemotherapy for CRPC, providing modest survival benefits [ 9– 11].
Overall survival has improved substantially over the past 12 years for Danish PC patients, including modest survival improvements among those with high comorbidity.
In the case of interferon, two randomised studies demonstrated a modest survival advantage for those who received the agent (MRCRC Collaborators, 1999; Pyrhonen et al, 1999).
Meta-analysis of several randomized trials have demonstrated a modest survival advantage for treatment with cisplatin-based regimens in patients with advanced stages of NSCLC [ 1, 2].
The primary result of this randomised trial shows a modest survival benefit for marimastat treatment in the overall population of gastric cancer patients.
These studies have been part of several meta-analyses, which could demonstrate no, or at the most a modest survival benefit for adjuvant chemotherapy [ 28- 33].
Apart from previous ADT, men with bone metastases and castrate-resistant prostate cancer would commonly receive chemotherapy given the results of initial phase III trials indicating modest survival benefit for those with symptomatic disease [ 15, 16].
In addition, despite chemotherapy, patients with advanced pancreatic cancer have a very modest survival, and for this reason, a placebo-controlled trial was considered ethically acceptable by investigators at University College Hospitals, London.
Unfortunately, current treatments for metastatic AIPC have demonstrated only modest survival advantages [7].
